Rallybio (RLYB)

Rallybio Stock Analysis & Ratings

RLYB Stock Chart & Stats

Day’s Range$10.7 - $11.66
52-Week Range$6.74 - $25.78
Previous Close$10.9
Average Volume (3M)105.59K
Market Cap$371.76M
P/E Ratio-7.5
Next EarningsSep 08, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)-1.54

Rallybio News

Currently, no data available
Please return soon. This page is being updated.




P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Rallybio’s price range in the past 12 months?
Rallybio lowest stock price was $6.74 and its highest was $25.78 in the past 12 months.
    What is Rallybio’s market cap?
    Rallybio’s market cap is $371.76M.
      What is Rallybio’s price target?
      The average price target for Rallybio is $31.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $36.00 ,the lowest forecast is $29.00. The average price target represents 173.73% Increase from the current price of $11.57.
        What do analysts say about Rallybio?
        Rallybio’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is Rallybio’s upcoming earnings report date?
          Rallybio’s upcoming earnings report date is Sep 08, 2022 which is in 113 days.
            How were Rallybio’s earnings last quarter?
            Rallybio released its earnings results on May 10, 2022. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.452 by -$0.028.
              Is Rallybio overvalued?
              According to Wall Street analysts Rallybio’s price is currently Undervalued.
                Does Rallybio pay dividends?
                Rallybio does not currently pay dividends.
                What is Rallybio’s EPS estimate?
                Rallybio’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Rallybio have?
                Rallybio has 32,130,000 shares outstanding.
                  What happened to Rallybio’s price movement after its last earnings report?
                  Rallybio reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.452. Following the earnings report the stock price went up 6.052%.
                    Which hedge fund is a major shareholder of Rallybio?
                    Among the largest hedge funds holding Rallybio’s share is New Leaf Venture Partners, L.L.C.. It holds Rallybio’s shares valued at 16M.


                      Rallybio Stock Analysis

                      The Rallybio stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description


                      Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

                      Similar Stocks
                      No data currently available

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis